A Nearby Corner of Synthetic Biology
Codexis (CDXS) sits in a nearby but distinct corner of the synthetic-biology field that Adam O’Dell’s Imperium pitch describes. It is not one of the promo’s picks, which center on Twist Bioscience and Ginkgo Bioworks (DNA), with Absci as the apps layer. Codexis is a comparison name, a way to see how the broader field breaks into different specialties, and its specialty is enzymes.
Enzymes are the workhorses of biology, the proteins that speed up chemical reactions. Codexis engineers them for pharmaceutical and industrial customers, designing proteins that do a specific job faster, cheaper, or more cleanly than the alternative. It is a different activity from what the Imperium picks do, which is part of why the comparison is useful.
What Enzyme Engineering Actually Is
Enzyme engineering is the practice of designing and improving the proteins that carry out chemical reactions. In plain terms, if DNA is the instruction manual, enzymes are the machines that follow the instructions. Codexis tweaks those machines so they work better for a particular task, whether that is manufacturing a drug ingredient or breaking down a material in an industrial process.
The distinction from the promo’s names matters. Twist Bioscience writes DNA, manufacturing the genetic instructions themselves. Ginkgo Bioworks programs cells and, in its current form, sells the robotic lab equipment to run biological experiments. Codexis works one layer up, engineering the proteins that do the actual chemistry. All three fall under the synthetic-biology umbrella, but they sell different things to different customers.
How Codexis Compares to the Imperium Names
O’Dell’s pitch leans on a specific framing, that the number one Imperium company is “over 600 times smaller than Nvidia” with a path to becoming the biggest company in the world. That framing is aimed at the picks at the center of the pitch, not at the comparison names around it, and it is a claim worth discounting: being smaller than Nvidia is not, by itself, an opportunity.
Codexis helps illustrate the range of companies the theme touches. The synthetic-biology field spans DNA synthesis, sequencing, cell programming, and enzyme engineering, and each corner has its own customers, competitors, and economics. Codexis competes in the enzyme-engineering corner, which sits alongside the tools and sequencing names that include Illumina, Thermo Fisher, and Danaher.
The Takeaway for Investors
The honest way to use a name like Codexis is as context, not as a substitute for the picks. O’Dell’s underlying claim, that DNA technology is getting faster and cheaper and that this matters across every industry that sells a molecule, is broadly correct. The field has attracted real money from DARPA, ARPA-H, the NSF, Amazon, Eli Lilly, and Anthropic, and Codexis is one more proof point that the umbrella is wide.
For the names at the center of the pitch, see our Twist Bioscience stock piece and our Ginkgo Bioworks stock piece. For the broader field, our synthetic biology explainer covers the lay of the land.
O’Dell’s track record is worth keeping in view. He teased Palantir in the $20s in spring 2024, and it became the best-performing stock in the S&P 500 for 2024, a real, checkable win. But the Imperium theme is a refreshed version of a pitch he has run since 2021, and the individual names underneath it have changed over time. Codexis is a useful neighbor to know, a company that shows how enzyme engineering fits into the same broad story, even though it is not the name O’Dell is selling.
Where Enzyme Engineering Sits in the Stack
It helps to place enzyme engineering in the same layered picture O’Dell uses. If Twist writes the instructions, and Ginkgo runs the lab, then a company like Codexis builds the machines that carry out the chemistry. In many industrial and pharmaceutical processes, the enzyme is the thing that actually does the work, and engineering a better enzyme can mean a cheaper drug, a cleaner manufacturing step, or a faster reaction. That is a real, commercially valuable activity, and it has been Codexis’s specialty for years.
The difference is one of focus. DNA synthesis and cell programming are about writing and running the code of life. Enzyme engineering is about refining the proteins that do the work, a step that sits downstream of the code itself. That means Codexis’s customers and competitors look different from the promo’s picks, even though all of them live under the same synthetic-biology umbrella.
The broader point is that the field O’Dell is describing is genuinely wide. It includes synthesis, sequencing, cell programming, and enzyme engineering, each with its own economics. That breadth is a strength of the theme, but it is also a reason to be specific about which corner any given name actually occupies. Codexis is the enzyme-engineering corner, a real and established specialty that is adjacent to, rather than the same as, the picks at the center of the Imperium pitch.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.